Ronald D. Perrone, MD, FASN, BRCU Faculty
Ronald D. Perrone, MD, FASN, has had a long-standing and wide-ranging interest in ADPKD. He has participated in all of the major clinical trials in ADPKD, serving as the Boston site Principal Investigator and member of the Steering Committees for the HALT PKD study, the TEMPO 3/4 and REPRISE trials of tolvaptan in ADPKD, the TAME-PKD study of metformin, and the Venglustat STAGED-PKD study. He also served as Boston site PI for the Tesevatinib and Bardoxolone (Falcon) studies.
Dr. Perrone has been a member of the Scientific Advisory Committee of the U.S. Polycystic Kidney Disease Foundation from 1999 to 2017 (Chairman from 2006-2010). He initiated and co-led the PKD Outcomes Consortium and has been the principal individual involved in bringing together the contributors from academia, pharma, NIH, FDA, EMA, CDISC, and C-Path. Total kidney volume has been approved as a prognostic biomarker by both the FDA and the EMA.